MESOTHELIOMA

This study was designed to test the drug alrizomadlin (APG-115) in people with BAP1 cancer syndrome who have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. However, the study was withdraw…

This early-stage study tests an experimental drug called SGN-MesoC2 in people with advanced solid tumors (like lung, ovarian, or pancreatic cancer) that have not responded to standard treatments. The drug is designed to attach to cancer cells and kill them. The main goals are to …

This early-phase study tests a new drug called KFA115, alone or with pembrolizumab, in people with advanced cancers like lung, melanoma, and kidney cancer. The main goal is to find a safe dose and understand side effects. About 126 participants will take part to see if the treatm…

This study tests a new radiation method (IMRT) given after surgery and chemotherapy for people with malignant pleural mesothelioma, a rare lung cancer. The goal is to see if this approach is safe and causes fewer lung side effects than standard radiation. About 65 adults with ear…

This study tests the drug pembrolizumab in about 1,600 people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can shrink tumors and to identify biomarkers that predict response. Participants receive pembrolizumab and are m…

This early-phase study tests an experimental oral drug called IAG933 in adults with advanced mesothelioma or other solid tumors that have certain genetic changes. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. About 137 partici…

This study tests an experimental drug called HFB200301, given alone or with another drug (tislelizumab), in adults with advanced solid tumors like stomach, kidney, or lung cancer. The goal is to find a safe dose and see how well people tolerate it. About 72 participants will take…

This early-stage trial tests a combination of two drugs, naptumomab estafenatox and durvalumab, in 120 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find safe doses and check for side effects, while also measur…

This study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have very early-stage mesothelioma. The goal is to see if the drug can stop the cancer from growing or improve it. About 9 participants will receive treatment and be monitored for…

This early-stage study tests the safety of a new drug, PF-08046049/SGN-BB228, in people with advanced melanoma and other solid tumors that have spread or are hard to treat. The study involves 41 participants and will look at side effects and the right dose. It is not expected to …

This study tests a treatment using a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells with a protein called mesothelin. It is for people with malignant pleural disease, including mesothelioma and cancers that have spread to the chest lining. …

This study tests a new program to help adults with lung cancer improve their quality of life after finishing cancer treatment. About 21 people will take part to see if the program is practical and acceptable. The goal is to support patients as they move from active treatment to r…

This study follows about 400 adults who previously received A2Bio gene therapy for various solid tumors, including lung, colon, and pancreatic cancers. The main goal is to track long-term safety and see how well the treatment effects last over time. Participants do not receive ne…

This research study aims to learn more about how chest cancers like lung cancer, thymus cancer, and mesothelioma develop and spread. Researchers will collect blood, tumor tissue, and other fluids from 1,000 adult participants to look for biological markers. The goal is to find cl…